Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

Researchers have turned artificial intelligence into a powerful new lens for understanding why cancer survival rates differ ...

For the first time, researchers have used machine learning—a type of artificial intelligence (AI)—to identify the most ...

Model was developed from the prostate cancer screening group of the PLCO and validated externally in a VA population ...

After radiation therapy, certain cancer patients face a lingering question: Is a troubling lesion a return of the cancer, or ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...

GSK licenses Noetik’s AI foundation models in anchor partnership to transform cancer therapeutic research and development ...

Pancreatic cancer is a rare disease; however, its initially inconspicuous symptoms and aggressive nature make it one of the deadliest forms of cancer.

Synthetic lethality may help overcome cancer therapeutic resistance by exploiting tumour vulnerabilities, supported by ...